| 品牌 | 货号 | 产品规格 | 价格(RMB) | 库存（上海） | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
| 源叶(MedMol) | S82515-5mg | 99% | ￥320.00元 | 5 | - | - | - |
|
| 源叶(MedMol) | S82515-10mg | 99% | ￥432.00元 | 6 | - | - | - |
|
| 源叶(MedMol) | S82515-25mg | 99% | ￥880.00元 | 5 | - | - | - |
|
| 源叶(MedMol) | S82515-100mg | 99% | ￥2240.00元 | 预计交期：2-3天 | - | - | - |
|
| 产品描述： PNU-282987 is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC50 of 154 nM. PNU-282987 is also a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM. PNU-282987 can be used for the research of central and peripheral nervous systems | ||||||||||||||||||||
| 靶点： IC50: 4541nM (5-HT3); EC50: 154 nM (α7 nAChR); Ki: 27 nM (R7 MLA);AChR | ||||||||||||||||||||
|
体外研究： PNU-282987 (Compound C7) displaces the R7 selective antagonist methyllycaconitine (MLA) from rat brain homogenates with a Ki of 27 nM. PNU-282987 has α7 nAChR agonist activity with an EC50 of 154 nM. PNU-282987 also has inhibition for the 5-HT3 receptor with an IC50 value of 4541nM |
||||||||||||||||||||
|
体内研究： PNU-282987 (Compound C7) (i.v.; 1, 3 mg/kg) leads to a reversal of the gating deficit. PNU-282987 (30 μM) evokes currents in rat hippocampal neurons in a concentration-dependent and MLA blockable manner. Animal Model: Rats Dosage: 1, 3 mg/kg Administration: i.v. Result: Significantly reversed amphetamine-induced gating deficit. |
||||||||||||||||||||
|
参考文献： 1. Alice L Bodnar, et al. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J Med Chem. 2005 Feb 24;48(4):905-8. |
||||||||||||||||||||
| 溶解性： Soluble in DMSO、H2O | ||||||||||||||||||||
| 保存条件： -20℃ | ||||||||||||||||||||
配置溶液浓度参考：
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
|---|
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京